Careplus Group (0163) Fair Value & Analysis
Healthcare · MY · Market cap 68.0M MYR
Fair value as of: Jun 26, 2026
Analysis
Careplus Group (0163) currently trades at 0.0800 MYR, while our model-based Fair Value estimate is 0.0320 MYR — implying the stock looks roughly 60.0% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Careplus Group Berhad, an investment holding company, manufactures and processes gloves in South America, North America, Malaysia, rest of Asia Pacific, and internationally. It offers latex exam gloves for use in medical examinations and procedures, diagnostic procedures by dentists, laboratory practices, and food handling practices; Nitrile examination gloves; and surgical gloves. The company also manufactures rubber gloves; manufactures, imports, and exports various types of hand gloves; develops and installs solar generation facilities; provides gloves packaging and warehousing services; offers hostel management and consultancy services, as well as involved in repairs and maintains buildings and its related works. In addition, it sells and deals in electric vehicles. Further, the company offers manufactures and assemblies new energy vehicles and leases and operates passenger cars. Additionally, it is involved in maintenance, repair, and sale of motor vehicles. Careplus Group Berh…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Careplus Group (0163) undervalued?
What is the fair value of 0163?
What is the quality score of 0163?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.